Television medical dramas traditionally resolve through diagnosis and intervention. Common Side Effects inverts this arc: its first episode ends with Dr. Thorne successfully curing a terminal pediatric patient, only to be immediately targeted by a joint task force from the FDA, the DEA, and a private health consortium called “The Remedium Group.” The series’ central thesis, articulated by Thorne in Episode 3, is that “A cure is a weapon. A chronic condition is a market.” Over 14 weeks, the show traces Thorne’s transformation from a rational scientist to a fugitive mycologist, hunted not for malpractice, but for the crime of efficacy. Drawing on Rob Nixon’s concept of “slow violence” and Achille Mbembe’s “necropolitics,” this paper argues that Common Side Effects is a rare mainstream text that treats the pharmaceutical industry not as corrupt in its malfeasance, but as rational in its lethal efficiency.
In a striking departure from genre conventions, Common Side Effects dedicates significant runtime to laboratory process. Episode 9 (“The Petri Dish and the Pendulum”) contains a 12-minute sequence of Thorne attempting to synthesize the fungus’s active compound, only to discover it requires a specific, non-reproducible mycorrhizal network that connects to old-growth forest root systems. The cure cannot be patented, scaled, or commodified. Remedium’s CEO, Miriam Hatch (Cherry Jones), delivers the season’s key monologue in Episode 11: “We don’t sell cures, Aris. We sell the management of not being dead. Your little mushroom turns patients into ex-customers. That is not medicine. That is bankruptcy.” The series thus critiques the “pharmacological gaze”—a term the show invents—as a medical epistemology that can only perceive treatable conditions, not resolvable ones. Thorne’s tragedy is not that he fails to distribute the cure; it is that he fails to understand that the system never wanted it to exist. Common Side Effects -2025-2025
Common Side Effects (2025–2026): Narrative Necropolitics and the Pharmacological Gaze in Late-Stage Capitalism A chronic condition is a market